



# Vol. 15 No. 4 (2021): Indian Journal of Forensic Medicine & Toxicology



DOI: <https://doi.org/10.37506/ijfmt.v15i4>

Published: 2021-09-05

## Articles

### Effectiveness of Empowerment Programme on Stress and Care Giving Burden among Care Givers of Chronically Ill Patients Admitted in MMIMS&R Hospital, Mullana Ambala, Haryana

Shalini Youssouf, Jyoti Sarin, Eenu, Bindu Joseph

1-8



### Study of Various Patterns of Azygos Venous System and its Clinical Significance

Aarti Rohilla, Monika Rathee, Kamal Singh, Suresh Kanta Rathee

9-13



### Fetal Ilium as a Tool For Sex Determination: Discriminant Functional Analysis

Aarti, Luv Sharma, Kamal Singh

14-21



### Review on Current Trends in Hypertension

Aarti Thakur, Ruchi Kumari, Sakshi Tomar



### **Effectiveness of Lockdown in Reducing the Spread of COVID-19**

Adyati Satya Puspita, Judya Sukmana, Lestari Dewi, Erina Yatmasari  
28-34



### **A Comparative Analysis of Misery Index and Its Impact on Health Indicators Across The Globe**

Aishwarya, Rajmohan, Suganya.P, Prabu.D, Bharathwaj, M.R.Prashanthu  
35-40



### **The Relationship of Perceived Benefit, Perceived Barrier, and Knowledge with Vaccine Hesitancy among Anti- and Pro- Vaccine Community**

Aisyah Nur Izzati, Retno Indarwati, Makhfudli  
41-48



### **Knowledge and Attitude Regarding Medication Error among Nursing Students in a Selected College at Mangaluru**

Ajanya Shaju, Aleesha Babu, Dona Sebastian, Mary Joseph, Pavithra K  
49-54



### **An Assessment of Oral Health Status among Lead Battery Factory Workers in Ghaziabad UP a Cross Sectional Study**

Akanksha Monga, Thanveer K, Bhuvandeep Gupta, Aparna Aggarwal, Nisha Yadav, Meena Jain, Ankur Sharma  
55-62



### **Cytotoxic Effect of Silver Nanoparticles Prepared by Biosurfactant Produced from Pathogenic Bacteria**

Aleaa Abdul Hussein Jameel, Nadhim Hussan Hayder, Amenah Rami Abdullah, Laith Ahmed Yaaqoob  
63-70



### **A Review on Medication Synchronization Programs in Community Pharmacies to Improve Medication Adherence**

Rakshith U.R, Srikanth M.S  
71-81



 Pdf

## **Risk Factors of Pre-Eclampsia of Women Birth From History of Eating Behavior During Pregnancy**

Teta Puji Rahayu, Suparji, Nana Usnawati

2716-2722

 Pdf

## **Array**

Teuku Heriansyah, Indah Nur Chomsy, Anwar Santoso, Muhammad Ridwan, FitriaNugraha Aini, Titin Andri Wihastuti

2723-2732

 Pdf

## **Isolation and Selective Drug of Chose for Pseudomonas Aeruginosa as a Causative Agent in Suppurative Otitis Media**

Thamer J Ghali, HusamOudah ALjwaid, Ali A. Al-Hisnawi, KasimSakran Abass

2733-2738

 Pdf

## **A Study of Epidemiology of Poisoning Cases Brought For Autopsy at Tertiary Health Care Centre in South-Western Maharashtra: A Ten-Year Retrospective Study**

Thippesh Kumar N, Sandeep Bansal, KV Radhakrishna, Sarala M, Shivakumar D Kalakabandi, Gautam Dhokia, Abhishek Rathee

2739-2747

 Pdf

## **A Woman with Tuberculosis Multidrug Resistance and QTc Prolongation Repetitive Interval: A Case Report**

Tutik Kusmiati, Ni Made Mertaniasih, Johannes Nugroho Eko Putranto, Budi Suprapti, Soedarsono, Abdul Rahman Bahmid

2748-2753

 Pdf

## **The Effect of Safety Management Practices Through Safety Knowledge Towards Safety Performance on Workers of Pt. Masmindo Dwi Area**

Ummu Kamilah, Syamsiar S. Russeng, Masyitha Muis, Yahya Thamrin, Masni, Fridawati Rivai, Rizky Maharja

2754-2762

 Pdf

## **Decreased Antioxidant Capacity in Corn Farmers Occupationally Exposed to the Mixture of Herbicides**

Unchisa Intayoung, Kanyapak Kohsuwan, Klintean Wunnapak, Ratana Sapbamrer, Supakit Khacha-Ananda

2763-2770

 Pdf

### **Mandibular Canine Index to Determine the Sex of the Individual- A Population based Study**

Varsha A Shetty, Vina Vaswani, Suraj Shetty, Mahabalesh Shetty

2771-2776

 Pdf

### **Application of Machine Learning and Deep Learning Technology in the Field of Dentistry among Top Five Gross Domestic Product (GDP) Countries - A Scientometric Analysis**

Varshini Rajendran, V.V.Bharathwaj, P.Suganya, D.Prabu, Rajmohan, M.R.Prashanth

2777-2784

 Pdf

### **Influence of Kappa-Casein and Beta-Lactoglobulin Genetic Variants on Milk Productivity of Red-and-White Cattle**

Velmatov, A.A, Dunin I.M., A. Al-Isawi, T.N. Tishkina

2785-2791

 Pdf

### **Radiology - A Specific Tool in Identification A Review**

Vinoth Kumar S, Monisha B. M

2792-2796

 Pdf

### **Concept of SARS-CoV-2 Vaccine Design to Fight COVID-19 Pandemic: A Review Insight**

Viol Dhea Kharisma, Arif Nur Muhammad Ansori, Rasyadan Taufiq Probojati, Dora Dayu Rahma Turista, Yulanda Antonius

2797-2803

 Pdf

### **Deleted**

2804-2813

### **How Do Patient Satisfaction in Dental Polyclinic? - Patient Characteristics and Quality of Dental Health Services**

Vitri Nurilawaty, Ngatemi, Dwi Priharti, Tedi Purnama, Ruth Lasma Milan

2814-2819

 Pdf

### **A Study Survey of Awareness of Jordanian Chemists about Chemical Hazards**

Waed R Alahmad, Tala H. Sasa, Nawal H Bahtiti, Ahmed Abu-Rayan

2820-2827

[HOME](#) / Editorial Team

## Editorial Team

### Editor in Chief

---

**M. Sinan BEKSAÇ**, Prof., Hacettepe University, Department of Perinatology, Ankara, Turkey  
([editor@gorm.com.tr](mailto:editor@gorm.com.tr)) [orcid.org/0000-0001-6362-787X](https://orcid.org/0000-0001-6362-787X)

### Editors

---

**Gürkan BOZDAĞ**, Prof., Koc University, Department of Reproductive Endocrinology, Ankara, Turkey  
[orcid.org/0000-0002-6679-9623](https://orcid.org/0000-0002-6679-9623)

**A. Seval ÖZGÜ ERDİNÇ**, Prof., Ministry of Health, Ankara City Hospital, Department of Obstetrics and Gynecology, Ankara, Turkey ([sevalerdinc@gmail.com](mailto:sevalerdinc@gmail.com)) [orcid.org/0000-0002-6132-5779](https://orcid.org/0000-0002-6132-5779)

**M. Coşkun SALMAN**, Prof., Hacettepe University, Ankara, Department of Obstetrics and Gynecology, Turkey [orcid.org/0000-0003-1504-1756](https://orcid.org/0000-0003-1504-1756)

### Associate Editors

---

**R. Atakan AL**, Prof., Atatürk University, Department of Obstetrics and Gynecology, Erzurum, Turkey [orcid.org/0000-0003-2921-1891](https://orcid.org/0000-0003-2921-1891)

**Belgin ATAÇ**, Prof., Baskent University, Ankara, Turkey [orcid.org/0000-0001-6868-2165](https://orcid.org/0000-0001-6868-2165)

**Hasan Tolga ÇELİK**, Assist. Prof., Hacettepe University, Department of Neonatology, Ankara, Turkey [orcid.org/0000-0002-1725-0722](https://orcid.org/0000-0002-1725-0722)

**Hanife Güler DÖNMEZ**, M.D., Hacettepe University, Ankara, Turkey [orcid.org/0000-0002-7413-4939](https://orcid.org/0000-0002-7413-4939)

**Erdem FADİLOĞLU**, M.D., Hacettepe University, Department of Perinatology, Ankara, Turkey [orcid.org/0000-0001-7953-2517](https://orcid.org/0000-0001-7953-2517)

**Ö. Tolga GÜLER**, Prof., Pamukkale University, Department of Obstetrics and Gynecology, Denizli, Turkey [orcid.org/0000-0001-6673-8604](https://orcid.org/0000-0001-6673-8604)

**İbrahim KALELİOĞLU**, Prof., Istanbul University, Çapa Medical School, Department of Perinatology, Istanbul, Turkey [orcid.org/0000-0002-5504-2166](https://orcid.org/0000-0002-5504-2166)

**Gökçen ÖRGÜL**, Assoc. Prof., Selcuk University ,Department of Perinatology, Konya, Turkey [orcid.org/0000-0003-0578-4230](https://orcid.org/0000-0003-0578-4230)

**Atakan TANACAN**, Assoc.Prof., Ministry of Health, Ankara City Hospital, Department of Perinatology, Ankara, Turkey [orcid.org/0000-0001-8209-8248](https://orcid.org/0000-0001-8209-8248)

## Sections

---

### Section Editors in Chief

---

**Aris J. ANTSAKLIS**, Prof., University of Athens, Department of Obstetrics and Gynecology, Athens, Greece [orcid.org/0000-0002-3855-5496](https://orcid.org/0000-0002-3855-5496)

**Acar KOÇ**, Prof., Ankara University, Department of Perinatology, Ankara, Turkey [orcid.org/0000-0003-2482-7478](https://orcid.org/0000-0003-2482-7478)

### Section Editors

---

#### **Maternal & Fetal Medicine**

**Recep HAS**, Prof., Istanbul University, Department of Perinatology, Istanbul, Turkey [orcid.org/0000-0002-1372-8506](https://orcid.org/0000-0002-1372-8506)

**Ratko MATIJEVIC**, Prof., University Hospital Merkur, Department of Obstetrics and Gynecology, Zagreb, Croatia [orcid.org/0000-0003-1693-7474](https://orcid.org/0000-0003-1693-7474)

**Nebojsa RADUNOVIC**, Prof., University of Belgrade, Department of Obstetrics and Gynecology, Belgrade, Serbia

**Atıl YÜKSEL**, Prof., Istanbul University, Department of Perinatology, Istanbul, Turkey [orcid.org/0000-0002-6487-0860](https://orcid.org/0000-0002-6487-0860)

#### **Perinatal Medicine**

**Apostolos P. ATHANASIADIS**, Prof., Papageorgiou Hospital, Aristotle University of Thessaloniki, Department of Obstetrics and Gynecology, Greece [orcid.org/0000-0001-8479-0916](https://orcid.org/0000-0001-8479-0916)

**Namık DEMİR**, Prof., Private Kent Hospital, Izmir, Turkey [orcid.org/0000-0003-1708-7870](https://orcid.org/0000-0003-1708-7870)

**Orion GLIOZHENI**, Prof., Spitalin University, Department of Obstetrics and Gynecology, Tiran, Albania

**Florin STAMATIAN**, Prof., Iuliu Hatieganu University of Medicine and Pharmacy, Department of

## Neonatology

**F.Emre CANPOLAT**, Assoc. Prof., University of Health Sciences Zekai Tahir Burak Health Practice and Research Center, Department of Neonatology, Ankara, Turkey [orcid.org/0000-0001-9307-3003](https://orcid.org/0000-0001-9307-3003)

**Esin KOÇ**, Prof., Gazi University, Department of Neonatology, Ankara, Turkey [orcid.org/0000-0003-3898-9857](https://orcid.org/0000-0003-3898-9857)

**Özge KÖROĞLU**, Assoc Prof, Ege University, Department of Neonatology, İzmir, Turkey [orcid.org/0000-0001-5998-0742](https://orcid.org/0000-0001-5998-0742)

**Milan STANOJEVIC**, Prof., Medical School University of Zagreb, Department of Neonatology, Zagreb, Croatia

## Reproductive Endocrinology & Infertility

**Engin TÜRKELDİ**, Prof., Koc University, Department of Reproductive Endocrinology, Ankara, Turkey [orcid.org/0000-0002-6679-9623](https://orcid.org/0000-0002-6679-9623)

**İbrahim ESİNLER**, Prof., Hacettepe University, Department of Reproductive Endocrinology, Ankara, Turkey [orcid.org/0000-0001-8117-0308](https://orcid.org/0000-0001-8117-0308)

**Tatjana MOTRENKO SIMIC**, M.D., Human Reproduction Centre Budva, Montenegro [orcid.org/0000-0002-4299-0423](https://orcid.org/0000-0002-4299-0423)

## Urogynecology, Andrology and Male Infertility

**Ali ERGEN**, Prof., Hacettepe University, Ankara, Turkey [orcid.org/0000-0001-7803-4217](https://orcid.org/0000-0001-7803-4217)

**Ciril J. GODEC**, Prof., Downstate College of Medicine, Brooklyn, NY, USA

## Gynecologic Oncology & Tumor Biology

**Ali AYHAN**, Prof., Baskent University, Ankara, Turkey [orcid.org/0000-0001-7155-9096](https://orcid.org/0000-0001-7155-9096)

**Nejat ÖZGÜL**, Prof., Hacettepe University, Ankara, Turkey [orcid.org/0000-0002-4257-9431](https://orcid.org/0000-0002-4257-9431)

**M. Mutlu MEYDANLI**, Prof., University of Health Sciences, Ankara City Hospital, Ankara, Turkey [orcid.org/0000-0001-6763-9720](https://orcid.org/0000-0001-6763-9720)

## Basic Science

**A. Nur ÇAKAR**, Prof., TOBB University, Ankara, Turkey [orcid.org/0000-0002-2585-7727](https://orcid.org/0000-0002-2585-7727)

**Dilek ŞAHİN**, Prof., University of Health Sciences, Ankara City Hospital, Department of Perinatology, Ankara, Turkey [orcid.org/0000-0001-8567-9048](https://orcid.org/0000-0001-8567-9048)

**Ibrahim A. Abdelazim**, Prof., Ain Shams University, Department of Obstetrics and Gynecology, Cairo, Egypt. [orcid.org/0000-0002-7241-2835](https://orcid.org/0000-0002-7241-2835)

**Gordana ADAMOVA**, Prof., Remedika General Hospital, Department of Obstetrics and Gynecology, Skopje, North Macedonia

**Saadet ARSAN**, Prof., Ankara University, Department of Neonatology, Ankara, Turkey [orcid.org/0000-0001-9320-7702](https://orcid.org/0000-0001-9320-7702)

**Şükriye AYTER**, Prof., TOBB University, Ankara, Turkey [orcid.org/0000-0003-1552-8804](https://orcid.org/0000-0003-1552-8804)

**Volkan BALTACI**, Prof., Genart Women's Health and Reproductive Biotechnology Centre, Ankara, Turkey [orcid.org/0000-0002-6626-8208](https://orcid.org/0000-0002-6626-8208)

**Güner BUŞ**, M.D. Private, Prizren, Kosova

**Merih BAYRAM**, Prof., Gazi University, Department of Perinatology, Ankara, Turkey [orcid.org/0000-0003-1299-2433](https://orcid.org/0000-0003-1299-2433)

**Seher BAŞARAN**, Prof., Istanbul University Istanbul, Turkey

**Snežana CRNOGORAC**, Prof., Podgorica, Montenegro

**A. Nuri DANIŞMAN**, Assoc. Prof., Acıbadem Altunizade Hospital, Istanbul, Turkey [orcid.org/0000-0001-7751-4710](https://orcid.org/0000-0001-7751-4710)

**Roumen DIMITROV**, Prof., Institute of Biology and Immunology of Reproduction, Bulgarian Academy of Sciences, Sofia, Bulgaria [orcid.org/0000-0002-7521-4439](https://orcid.org/0000-0002-7521-4439)

**Jadranka DIZDAREVIC**, Prof., Medical Faculty in Sarajevo, Bosnia and Herzegovina

**İlkan DÜNDAR**, Prof., Private Florence Nightingale Hospital, Istanbul, Turkey

**Yasser Nabawy ELSAYED**, Assistant Prof. University of Manitoba, Department of Neonatology, Winnipeg, Manitoba, Canada

**Valentin FRIPTU**, Prof., Doctor Habilitat in Medicină, Moldavia, Romania,

**Antonios GOUNARIS**, M.D., University Hospital of Larissa, University of Thessaly, Department of Obstetrics and Gynecology, Larissa, Greece

**Kadri Şafak GÜÇER**, Prof., Hacettepe University, Ankara, Turkey [orcid.org/0000-0002-6021-4612](https://orcid.org/0000-0002-6021-4612)

**Serkan GÜÇLÜ**, Prof., Private Kent Hospital, İzmir, Turkey

**Marija HADZI LEGA**, Prof., University of Skopje, North Macedonia [orcid.org/0000-0002-5521-4685](https://orcid.org/0000-0002-5521-4685)



**Dominic ILIESCU**, M.D., University of Medicine and Pharmacy Craiova, Department of Obstetrics and Gynecology, Romania [orcid.org/0000-0002-7823-3387](https://orcid.org/0000-0002-7823-3387)

**Necat İMİRZALIOĞLU**, Prof., HRS Clinic, Ankara, Turkey

**Joannis KALLIKAS**, M.D., Makarios Hospital, Nicosia, Cyprus

**Ergun KARAAĞAOĞLU**, Prof., Hacettepe University, Ankara, Turkey [orcid.org/0000-0002-7024-7231](https://orcid.org/0000-0002-7024-7231)

**Christina KARAOLI**, Prof., Hospital Archbishop Makarios III, Nicosia, Cyprus

**Deniz KARÇAALTINCABA**, Assoc. Prof., Gazi University, Department of Perinatology, Ankara, Turkey [orcid.org/0000-0001-5276-9303](https://orcid.org/0000-0001-5276-9303)

**Sedef KIR**, Prof., Hacettepe University, Ankara, Turkey

**Goran KOCOSKI**, M.D., University of SS Ciril and Methodius, Skopje, North Macedonia

**Ayşe KORKMAZ TOYGAR**, Prof., Acıbadem University, Istanbul, Turkey

**Olivera KONTIC VUCINIC**, Prof., University of Belgrad, Department of Obstetrics and Gynecology, Serbia

**Arda LEMBET**, Assoc. Prof., Private Femical Clinic, Istanbul, Turkey

**George MAKRYDIMAS**, Assoc. Prof., University Hospital of Ioannina, Ioannina, Greece

**Valentina MAZNEIKOVA**, Prof., St.Sofia Medical Center, Medical University, Sofia, Bulgaria

**İnanç MENDİLCİOĞLU**, Prof., Akdeniz University, Department of Perinatology, Antalya, Turkey [orcid.org/0000-0001-5611-5518](https://orcid.org/0000-0001-5611-5518)

**Rubena MOISIU**, Prof., Spitalin University, Tiran, Albania

**Özlem MORALOĞLU TEKİN**, Prof., University of Health Sciences, Ankara City Hospital, Department of Obstetrics and Gynecology, Ankara, Turkey [orcid.org/0000-0001-8167-3837](https://orcid.org/0000-0001-8167-3837)

**Daniel MURESAN**, Assoc. Prof., University of Medicine And Pharmacy, Department of Obstetrics and Gynecology, Cluj Napoca, Romania [orcid.org/0000-0002-7744-0501](https://orcid.org/0000-0002-7744-0501)

**Sevda MÜFTÜOĞLU**, Prof., Hacettepe University, Ankara, Turkey [orcid.org/0000-0003-0664-0204](https://orcid.org/0000-0003-0664-0204)

**Sezcan MÜMÜŞOĞLU**, Assoc. Prof., Hacettepe University, Department of Reproductive Endocrinology, Ankara, Turkey [orcid.org/0000-0001-7000-7580](https://orcid.org/0000-0001-7000-7580)

**Emirhan NEMUTLU**, Assoc. Prof., Hacettepe University, Ankara, Turkey [orcid.org/0000-0002-7337-6215](https://orcid.org/0000-0002-7337-6215)

**Firat ORTAÇ**, Prof., Ankara University, Department of Obstetrics and Gynecology, Ankara, Turkey

**Mircea ONOFRIESCU**, Prof., Grigore T. Popa University of Medicine and Pharmacy, Department of Obstetrics and Gynecology, Iasi, Romania [orcid.org/0000-0001-9905-7135](https://orcid.org/0000-0001-9905-7135)

**Hakan ÖZKARDEŞ**, Prof., Baskent University, Ankara, Turkey [orcid.org/0000-0002-7277-449X](https://orcid.org/0000-0002-7277-449X)

**Özgür ÖZYÜNCÜ**, Prof., Hacettepe University, Department of Perinatology, Ankara, Turkey [orcid.org/0000-0003-3256-5762](https://orcid.org/0000-0003-3256-5762)

**Apostolos PAPAGEORGIOU**, Prof., Jewish General Hospital, Canada [orcid.org/0000-0001-9082-4676](https://orcid.org/0000-0001-9082-4676)

**Nikolaos PAPANTONIOU**, Prof., Attikon Hospital, University of Athens, Greece [orcid.org/0000-0002-5571-5703](https://orcid.org/0000-0002-5571-5703)

**Snezana PLESINAC**, Assoc. Prof., University of Belgrade, Serbia

**Tanja PREMUR**, M.D., University of Ljubljana, Ljubljana, Slovenia [orcid.org/0000-0003-2597-0188](https://orcid.org/0000-0003-2597-0188)

**Milica RANKOVIC JANEVSKI**, Prof., Institute of Neonatology, Belgrade, Serbia

**Sasa SAVIC**, University of Banja Luka, Republic of Srpska, Department of Obstetrics and Gynecology, Bosnia Herzegovina [orcid.org/0000-0002-1611-4024](https://orcid.org/0000-0002-1611-4024)

**Stavros SIFAKIS**, Prof., University of Crete, Department of Obstetrics and Gynecology, Crete, Greece

**Goran STOJKANOVIC**, Prof., Clinical Center of Sarajevo University, Sarajevo, Bosnia and Herzegovina

**Nenad SULOVIĆ**, M.D., University of Belgrade, Department of Obstetrics and Gynecology, Belgrade, Serbia

**Feride SÖYLEMEZ**, Prof., Ankara University, Department of Perinatology, Ankara, Turkey [orcid.org/0000-0002-0816-5577](https://orcid.org/0000-0002-0816-5577)

**H. Mete TANIR**, Prof., Osmangazi University, Department of Perinatology, Eskişehir, Turkey [orcid.org/0000-0003-2980-630X](https://orcid.org/0000-0003-2980-630X)

**Yasemin TAŞCI**, Prof., Kütahya Dumlupınar University, Department of Obstetrics and Gynecology, Ankara, Turkey [orcid.org/0000-0002-6612-7042](https://orcid.org/0000-0002-6612-7042)

**Vajdana TOMIĆ**, Prof., University of Mostar, Department of Obstetrics and Gynecology, Mostar, Bosnia and Herzegovina [orcid.org/0000-0002-0469-7840](https://orcid.org/0000-0002-0469-7840)

**Kornelija TRAJKOVA**, Prof., University Ob/Gyn Clinic Skopje, Acibadem Sistina Hospital, North Macedonia

**Christos TSAKALIDIS**, M.D, General Papageorgiou Hospital, Aristotle University of Thessaloniki,

Department of Obstetrics and Gynecology, Thessaloniki, Greece

**Selçuk TUNCER**, Prof., Hacettepe University, Ankara, Turkey

**Bülent URMAN**, Prof., Koc University, Department of Reproductive Endocrinology, Istanbul, Turkey [orcid.org/0000-0002-6076-6468](https://orcid.org/0000-0002-6076-6468)

**Radu VLADEREANU**, Prof., Elias University Emergency Hospital, Bucharest, Romania

**John WILLIAMS III**, Prof., Cedars Sinai Medical Center, LA, USA

**Ömer T. YALÇIN**, Prof., Osmangazi University, Department of Obstetrics and Gynecology, Eskişehir, Turkey [orcid.org/0000-0001-5626-1881](https://orcid.org/0000-0001-5626-1881)

**Filiz YANIK**, Prof., Private Medicine, Ankara, Turkey [orcid.org/0000-0002-2034-413X](https://orcid.org/0000-0002-2034-413X)

**Hakan YARALI**, Prof., Hacettepe University, Ankara, Turkey [orcid.org/0000-0002-3170-0566](https://orcid.org/0000-0002-3170-0566)

**Fehmi YAZICIOĞLU**, M.D., Private Medicine, Istanbul, Turkey [orcid.org/0000-0003-1979-6144](https://orcid.org/0000-0003-1979-6144)

**Nafiye YILMAZ**, Prof., University of Health Sciences, Ankara City Hospital, Department of Reproductive Endocrinology, Ankara, Turkey [orcid.org/0000-0002-4041-297X](https://orcid.org/0000-0002-4041-297X)

**Murat YURDAKOK**, Prof., Hacettepe University, Department of Neonatology, Ankara, Turkey [orcid.org/0000-0002-6890-9224](https://orcid.org/0000-0002-6890-9224)

**Kunter YÜCE**, Prof., Hacettepe University, Department of Obstetrics and Gynecology, Ankara, Turkey [orcid.org/0000-0001-7768-8278](https://orcid.org/0000-0001-7768-8278)

**Aykan YÜCEL**, Prof., University of Health Sciences, Ankara City Hospital, Ankara, Department of Perinatology, Turkey [orcid.org/0000-0002-5888-692X](https://orcid.org/0000-0002-5888-692X)

**Şule YİĞİT**, Prof., Hacettepe University, Ankara, Turkey [orcid.org/0000-0002-8755-0384](https://orcid.org/0000-0002-8755-0384)

**Hulusi B. ZEYNELOĞLU**, Prof., Baskent University, Department of Reproductive Endocrinology, Ankara, Turkey [orcid.org/0000-0002-0289-2642](https://orcid.org/0000-0002-0289-2642)

OFFICIAL PUBLICATIONS OF

Maternal-Fetal Medicine and Perinatology Society



PUBLISHER



Atakan Sokak No:22/6 Mecidiyeköy Şişli/İstanbul

[www.medicalnetwork.com.tr](http://www.medicalnetwork.com.tr)

INDEXING AND ABSTRACTING IN

- Academic Resource Indexing (ResearchBib)
- CiteFactor
- DOAJ
- DRJI
- Gale

- Geneva Foundation for Medical Education and Research
- Google Scholar
- J-Gate
- JournalTOCs
- Miar (Information Matrix for the Analysis of Journals)
- National Library of Medicine Catalog (NLM Catalog)
- ResearchGate
- ROAD
- Scilit
- Scopemed
- TUBITAK ULAKBİM Turkish Medical Database (ULAKBİM Tıp Veri Tabanı [Türk Tıp Dizini])
- Türk Medline Ulusal Sağlık Bilimleri Süreli Yayınlar Veritabanı
- Worldcat OCLC

MEMBERSHIP

**ICMJE** INTERNATIONAL COMMITTEE *of*  
MEDICAL JOURNAL EDITORS



**Crossref**



Gynecology Obstetrics and Reproductive Medicine  
ISSN: 1300-4751 E-ISSN: 2602-4918

Copyright © Author(s)

[MEBAS Medikal Basın Yayın ve Tanıtım Ajans San. ve Tic. Ltd. Şti.](#)

# A Woman with Tuberculosis Multidrug Resistance and QTc Prolongation Repetitive Interval: A Case Report

Tutik Kusmiati<sup>1</sup>, Ni Made Mertaniasih<sup>2</sup>, Johannes Nugroho Eko Putranto<sup>3</sup>, Budi Suprapti<sup>4</sup>, Soedarsono<sup>5</sup>, Abdul Rahman Bahmid<sup>6</sup>

<sup>1</sup>Medical Staff, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia, <sup>2</sup>Professor, Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia, <sup>3</sup>Associate Professor, Department of Vascular and Cardiology Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia, <sup>4</sup>Associate Professor, Faculty of Pharmacy, Universitas Airlangga – Universitas Airlangga Teaching Hospital, Surabaya, Indonesia, <sup>5</sup>Associate Professor, Department of Pulmonology and Respiratory Medicine, <sup>6</sup>Resident, Pulmonology and Respiratory Medicine, Universitas Airlangga – Universitas Airlangga Teaching Hospital, Surabaya, Indonesia

## Abstract

**Background** : Prolonged QTc interval is one of the side effects of the short-regimen MDR-TB. QTc prolongation is a risk factor for Torsades de pointes and is influenced by many factors. **Case** : 47-year-old woman who was diagnosed with MDR-TB through GeneXpert examination and received short-regimen MDR-TB. This patient experienced repeated QTc prolongation, with peak QTc interval 600 msec occurring at 4th month with mild hypokalemia without clinical symptoms. The patient completed 9 months of short-regimen therapy with improve chest x ray followed by negative sputum culture. **Conclusion** : Short-regimen MDR-TB contains several drugs that cause QTc prolongation. Clinical evaluation is required in patients with QTc prolongation before changing the regimen.

**Keywords:** TB-MDR, QTc prolongation, Moxifloxacin

## Introduction

Multidrug-resistant tuberculosis (MDR-TB) is still a world health problem and a threat to TB control globally. WHO estimates that there are about 3.3% new MDR TB cases and 20% MDR TB re-treatment cases. Several factors that contribute to the spread of MDR-TB, especially in endemic areas, include

limited treatment options, high costs, ineffective and prolonged therapy. In 2016 WHO announced a short-term regimen for MDR-TB therapy that is expected to reduce costs, reduce costs and be effective for MDR-TB patients worldwide. This regimen consists of kanamicin, moxifloxacin, etonamide, clofazimin, pyrazinamide and high doses of INH for 4-6 months of the intensive phase and is followed by a follow-up phase consisting of moxifloxacin, clofazimin, pyrazinamide and ethambutol for 5 months<sup>(1,2)</sup>.

Although the short-term MDR-TB regimen brings new hope, this cannot be separated from the side effects caused by some MDR-TB drugs, one of which is the lengthening of the corrected QT (QTc) interval. QTc prolongation is a risk factor for the incidence of Torsades de Pointes (TdP) as well as arrhythmias that have the

---

### Corresponding Author:

**Tutik Kusmiati**

Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Jalan Mayjend Prof. Dr. Moetopo 6 – 8, Airlangga, Gubeng, Surabaya 60286, Indonesia, Mail: tut.kusmiati@gmail.com  
Phone: +6231-5501656,  
Orcid ID: 0000-0002-5686-2377



potential to cause death. According to a review study the prevalence of sudden death due to TdP due to QTc prolongation due to MDR-TB drugs may be less than 1%. Electrocardiogram (ECG) monitoring is required in MDR-TB patients receiving short-term therapy, but in resource-limited areas this is neither a limitation nor a condition of using short-term MDR-TB regimens (2, 3).

The QT interval is the portion of the EKG that is calculated from the start of the QRS complex to the end of the T wave, it describes the time it takes for the ventricular myocardium to depolarize and repolarize or the time it takes the myocardium to replenish between heartbeats measured in seconds (s) or milliseconds (ms). The QT interval is influenced by heart rate, which can shorten at a fast heart rate and lengthen at a slow heart rate so the QT interval needs to be corrected. The QT or QTc correction formula is needed to estimate the QT interval at a heart rate of 60 times a minute. The normal value of QTc in men <450 ms and in women <470 ms (4, 5).

Fluoroquinolones (FQ) are one of the most effective mycobactericidal classes. FQ has also been noted to cause prolongation of QTc and TdP especially in the elderly population. All FQ can be used for MDR-TB treatment including Levofloxacin (Lfx) and Moxifloxacin (Mfx). Mfx was noted to be the FQ that caused more QTc lengthening than the other FQs (5, 6). Based on the above description we are interested in reporting a recurrent case of MDR TB and QTc prolongation interval in a woman.

### Case Presentation

A 47-years-old woman with a previous history of failure to treat category 1 OAT was diagnosed with rifampicin-resistant pulmonary TB by geneXpert examination. The results of the x-ray examination obtained the results according to figure 1. Patients received MDR TB therapy including Kanamicin (Km) 750 mg, moxifloxacin (Mfx) 600 mg, clofazimine (Cfz) 100 mg, Ethionamid (Eto) 500 mg, isoniazid (H) 600

mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 800 mg. Before starting therapy, the patient was previously carried out a baseline examination, including a complete laboratory examination, electrocardiogram (EKG), audiometry and psychology.

After receiving therapy for 1 week the patient experienced prolonged QTc interval 545 msec, without laboratory abnormalities or clinical symptoms. Mfx was stopped for 3 days and an EKG was evaluated every day. After the QTc interval returned to normal (411 msec), Mfx was started at a dose of 400 mg. A week later the QTc interval of 468 msec and Mfx was again given at a dose of 600 mg while evaluating the ECG (Figure 2 & Table 1).

When entering the advanced stage of therapy, the patient again experienced a prolonged QTc interval of 600 msec so that Mfx was temporarily stopped and a laboratory evaluation was carried out. The laboratory results at that time showed that the patient had mild hypokalemia with a potassium value of 3.2 mmol/l. After correction of hypokalemia the QTc interval returns to normal and Mfx is started again at a dose of 200 mg for 7 days, and then continued at a dose of 400 mg until the end of therapy.

Entering the 7th month of therapy, the patient again experienced a prolonged QTc interval of 539 msec, without clinical symptoms and laboratory abnormalities (potassium 3.7 mmol/l). Currently Mfx is still given at a dose of 400 mg but the Cfz dose is reduced to 50 mg/day. After a week of evaluation the QTc returned to normal and Cfz was again given at a dose of 100 mg/day until the end of treatment. The patient had conversion of Acid-fast bacilli at 4th month followed by negative sputum culture until the end of therapy. The patient experienced clinical and radiological improvement, at the seventh month the treatment was completed and the patient was declared cured.




**Table 1. QTc Serial**

Time	QTc interval	Action
2nd week	545 msec	Mfx temporary stop
1st month	468 msec	Mfx 600 mg
2nd month	471 msec	Mfx 600 mg
4th month	600 msec	Mfx temporary stop
4th month	443 msec	Mfx 200 mg
5th month	491 msec	Mfx 400 mg
7th month	539 msec	Mfx 400 mg + Cfz 50 mg
7th month	433 msec	Mfx 400 mg + Cfz 100 mg

**Table 2. Risk factors for QTc prolongation and torsades de pointes**

Baseline and unmodified predisposition	Acquired risk factors : clinical condition
<ul style="list-style-type: none"> <li>- Underlying conduction abnormalities (subclinical long QT syndrome) : genetic predisposition, family history of sudden death</li> <li>- Bradycardia</li> <li>- Female sex</li> <li>- Advanced age (linearly increased risk after 60 years)</li> </ul>	<ul style="list-style-type: none"> <li>- Electrolyte imbalance : hypokalaemia, severe hypomagnesaemia, hypocalcaemia</li> <li>- Structural and functional heart problems : recent conversion from atrial fibrillation, ischaemic and congestive heart disease, ischaemic cardiomyopathy, dilated or hypertrophic congestive heart disease, congestive heart failure</li> <li>- Frequent conditions of TB patients : HIV infection, low BMI (malnutrition, starvation, and wasting syndrome), severe vomiting and diarrhea creating low potassium levels</li> <li>- Impaired renal function</li> <li>- Impaired hepatic function</li> <li>- Hypothyroidism</li> </ul>



**Figure 1A. Chest X-Ray at baseline; B. Chest X-Ray after 6 month therapy; C. Chest X-Ray end of therapy**




Figure 2A. ECG baseline with QTc 398 Msec; B. ECG after 4th month therapy with QTc 600 Msec.

## Discussion

Prolonged QTc interval greater than 500 msec is generally thought to increase the risk of developing TdP in the majority of the group with congenital long QT syndrome. The risk of TdP or sudden death is not always directly related to the length of the QT interval or the duration of QTc prolongation during therapy, but it can still be influenced by many factors. Drug-induced QTc prolongation has different properties from drug to drug. All FQs were noted to cause QTc prolongation, but according to case reports Mfx has the greatest risk of causing QTc prolongation<sup>(2, 3)</sup>. The risk of QTc prolongation with FQ will be higher if there are electrolyte abnormalities and the use of other drugs that cause QTc prolongation<sup>(5, 6)</sup>. In this case, when the patient experienced QTc lengthening of 600 msec, there

was also mild hypokalemia (potassium 3.2 mmol/l). Apart from stopping Mfx we also provide potassium intake to the patient.

A 2018 Indian study involving 467 patients receiving the Mfx regimen after a 4-month evaluation did not show a significant increase in QTc. Although there were 5 patients who experienced prolonged QTc interval, Mfx had to be temporarily stopped and given again without experiencing a cardiac event. According to the study Mfx 400 mg daily given for 4 months did not cause prolonged QTc interval<sup>(7)</sup>.

In a South Korean study of 373 MDR-TB or NTM-TB patients receiving Mfx, Cfx and macrolide therapy, significant QTc prolongation occurred in 16.7% of patients with a maximum QTc value of 451 msec and a mean QTc lengthening of 33.6 msec from baseline.

This study concluded that drug combinations that cause QTc changes in MDR-TB or NTM therapy are generally safe to use<sup>(8)</sup>. Although Mfx significantly caused QTc prolongation it was of moderate duration with a mean increase of 4% in the therapeutic dose of 400 mg. The effect of Mfx on ventricular repolarization occurs primarily at times of maximum plasma concentration, but QTc prolongation may be decreased with repeated administration, therefore the risk of TdP is small at 400 mg/day<sup>(9)</sup>. In this case, QTc prolongation still occurred in the advanced phase of therapy even though Mfx had been given at a dose of 400 mg/day, this might occur because the patient was still receiving other drugs that caused QTc interval lengthening, which is Cfz. After receiving low dose Cfz (50mg/day), QTc returned to normal. Although the evidence is limited, Cfz has been noted to increase QTc interval between 10-20 msec<sup>(10)</sup>.

Apart from FQ, there are several antibiotics used in MDR-TB therapy that are associated with prolongation of the QTc interval, such as bedaquilin, delamanid, and Cfz. The safety of using Mfx together with any of these drugs in MDR-TB therapy requires further clinical evaluation (Table 2). Until now, the incidence of TdP in clinical trials of TB patients is very rare, because the field conditions are difficult to evaluate for cardiotoxicity<sup>(10)</sup>. One study showed that the risk of Mfx-associated QTc prolongation was increased in individuals with certain genotypes<sup>(11)</sup>.

### Conclusion

QTc prolongation is one of the side effects of the short-term MDR-TB regimen. This can be related to several factors, including the combination of several drugs that cause QTc prolongation, and certain clinical conditions, especially electrolyte disturbances. Although the incidence of TdP associated with QTc prolongation in MDR-TB therapy is rare, ECG evaluation in patients receiving short-term MDR-TB therapy is needed. Therefore a clinical evaluation should be carried out in patients experiencing QTc prolongation before stopping or changing their MDR-TB treatment regimen.

**Conflict of Interest:** The authors report no conflict of interest in this publish.

**Funding:** None.

**Ethical Approval:** All procedures performed in studies involving human participants were in accordance declaration of helsinki the Ethics Committee in Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.

### References

1. Bansal R, Sharma D, Singh R. Tuberculosis and its Treatment: An Overview. *Mini Rev Med Chem.* 2018;18(1):58-71.
2. Kusmiati T, Charisma AN, Nugroho NPS. Drug-Resistant Tuberculosis: Correlation between Positivity of Acid-Fast Bacilli Sputum and Time to Conversion on Patients With Short-Term Treatment Regimen. *Journal of Pure and Applied Microbiology.* 2020;14(4).
3. Monedero-Recuero I, Hernando-Marrupe L, Sánchez-Montalvá A, Cox V, Tommasi M, Furin J, et al. QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.* 2018.
4. Lange C, Abubakar I, Alffenaar J-WC, Bothamley G, Caminero JA, Carvalho ACC, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. *Eur Respir J.* 2014;44(1):23-63.
5. Katrak S, Lowenthal P, Shen R, True L, Henry L, Barry P. Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California. *J Clin Tuberc Other Mycobact Dis.* 2021;23:100216.
6. Soeroto AY, Lestari BW, Santoso P, Chaidir L, Andriyoko B, Alisjahbana B, et al. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study. *PloS one.* 2019;14(2):e0213017.
7. Nair D, Velayutham B, Marimuthu M, Navaneethapandian PGD, Chinnaiyan P, Jawahar

- MS, et al. Effect of moxifloxacin on QTc interval in adults with pulmonary tuberculosis. *The National medical journal of India*. 2018;31(1):58-9.
8. Yoon HY, Jo KW, Nam GB, Shim TS. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. 2017;21(9):996-1001.
  9. Démolis JL, Kubitza D, Tennezé L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. *Clinical pharmacology and therapeutics*. 2000;68(6):658-66.
  10. Sterling TR. Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. 2016;20(12):42-7.
  11. Weiner M, Gelfond J, Johnson-Pais TL, Engle M, Peloquin CA, Johnson JL, et al. Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis. *Antimicrob Agents Chemother*. 2018;62(5):e01802-17.